Alma Fulurija

Dr

  • The University of Western Australia (M504), 35 Stirling Highway, Room 2.11, L Block, QEII Medical Centre

    6009 Perth

    Australia

  • 535 Citations
  • 12 h-Index
19942017
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Dr. Alma Fulurija was awarded her PhD in Pathology/Immunology in 2002 from University of Western Australia. She subsequently received post-doctoral training at the WHO Collaborating Centre for Immunology and Vaccinology in Geneva and spent a further five years as a Senior Scientist with Cytos Biotechnology Ltd, voted the most successful Swiss biotech company in 2006/07. She relocated back to Australia in 2007 to join Ondek Pty Ltd as a Senior Immunologist and to take up the Adjunct position at UWA.

Roles and responsibilities

Dr. Alma Fulurija holds the position of Adjunct Senior Lecturer at the University of Western Australia in the School of Biology, Biochemistry and Chemical Sciences (Discipline of Microbiology and Immunology) and Head of Immunology at Ondek Pty Ltd, a start-up biotech company founded by Prof. Barry Marshall and hosted by UWA. She has proven skills in immunology, microbiology, in vivo animal models and in vaccine development, particularly immunotherapy. She has gained international experience in both academic and applied research which has led to scientific publications and patents. Dr Fulurija has strong experience in both preclinical animal models and human clinical trials of vaccine-based immunotherapy.

Current projects

Dr. Fulurija’s research interests are in host-pathogen interactions, host defence mechanisms and immunotherapy. In addition to the development of an innovative vaccine delivery technology based on H. pylori, she has a strong interest in investigating H. pylori pathogenesis. Of particular interest is the contribution of the early (innate) immune response and its role in eliciting a non-protective immune response. The current grant aims to understand the molecular mechanisms of survival and persistence of H. pylori by looking at early colonisation events such as phagocytosis.

Teaching overview

•Co-supervising: 2 PhD students in addition to the supervision of Ondek’s immunology team (1 research assistant, 2 postdoctoral scientist)
•Lecturing to Undergraduate students in immunology (2007-current)
•Lecturing to Masters students at the Marshall Centre of Infectious Disease Research and Training (2008-current)

Keywords

  • <i>H. pylori</i> host-pathogen interactions
  • Immunology
  • Vaccine development
  • <i>H. pylori</i> pathogenesis

Fingerprint Dive into the research topics where Alma Fulurija is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles
Candida albicans Medicine & Life Sciences
Helicobacter pylori Medicine & Life Sciences
Infection Medicine & Life Sciences
Complement C5 Medicine & Life Sciences
Inbred DBA Mouse Medicine & Life Sciences
Kidney Medicine & Life Sciences
DNA Topoisomerase IV Medicine & Life Sciences
DNA Restriction-Modification Enzymes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1994 2017

8 Citations (Scopus)

Helicobacter pylori gene silencing in vivo demonstrates urease is essential for chronic infection

Debowski, A. W., Walton, S. M., Chua, E-G., Tay, A. C-Y., Liao, T., Lamichhane, B., Himbeck, R., Stubbs, K. A., Marshall, B. J., Fulurija, A. & Benghezal, M., Jun 2017, In : PLoS Pathogens. 13, 6, 21 p., 1006464.

Research output: Contribution to journalArticle

Open Access

The redefinition of Helicobacter pylori lipopolysaccharide O-antigen and core-oligosaccharide domains

Li, H., Yang, T., Liao, T., Debowski, A. W., Nilsson, H., Fulurija, A., Haslam, S., Mulloy, B., Dell, A., Stubbs, K. A., Marshall, B. J. & Benghezal, M., Sep 2017, In : Helicobacter. 22, 1 p.

Research output: Contribution to journalAbstract/Meeting Abstract

8 Citations (Scopus)

The redefinition of Helicobacter pylori lipopolysaccharide O-antigen and core-oligosaccharide domains

Li, H., Yang, T., Liao, T., Debowski, A. W., Nilsson, H. O., Fulurija, A., Haslam, S. M., Mulloy, B., Dell, A., Stubbs, K. A., Marshall, B. J. & Benghezal, M., 17 Mar 2017, In : PLoS Pathogens. 13, 3, e1006280.

Research output: Contribution to journalArticle

Open Access
O Antigens
Oligosaccharides
Heptoses
Ligases
Helicobacter pylori

Helicobacter pylori overcomes natural immunity in repeated infections

Stenström, B., Windsor, H. M., Fulurija, A., Benghezal, M., Kumarasinghe, M. P., Kimura, K., Tay, C. Y., Viiala, C. H., Ee, H. C., Lu, W., Schoep, T. D., Webberley, K. M. & Marshall, B. J., Nov 2016, In : Clinical Case Reports. 4, 11, p. 1026-1033 8 p.

Research output: Contribution to journalArticle

Open Access
Innate Immunity
Helicobacter pylori
Vaccines
Helicobacter Infections
Infection

Persistence of Helicobacter pylori Infection: Genetic and Epigenetic Diversity

Benghezal, M., Gauntlett, J., Debowski, A., Fulurija, A., Nilsson, H-O. & Marshall, B., 2014, Trends in Helicobacter pylori Infection. Roesler, B. M. (ed.). Rijeka, Croatia: InTech, p. 3-76

Research output: Chapter in Book/Conference paperChapter

Projects 2014 2017